RedHill Biopharma Ltd.
NASDAQ: RDHL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Dror Ben-Asher
- Employees
- 35
- Headquarters
- Tel Aviv, Israel
- IPO year
- 2013
- Market cap
- $2.9M
- Website
- https://www.redhillbio.com
Loading RDHL…
Loading profile data…Frequently asked questions about RDHL
What does RedHill Biopharma Ltd. (RDHL) do?
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Hel...
Where does RDHL trade?
RedHill Biopharma Ltd. (RDHL) trades on the NASDAQ Global Market.
What sector is RDHL in?
RedHill Biopharma Ltd. (RDHL) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of RedHill Biopharma Ltd.?
Dror Ben-Asher is the chief executive officer of RedHill Biopharma Ltd. (RDHL).
Where is RedHill Biopharma Ltd. headquartered?
RedHill Biopharma Ltd. is headquartered in Israel.
Does RDHL pay a dividend?
RedHill Biopharma Ltd. (RDHL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RDHL go public?
RedHill Biopharma Ltd. (RDHL) completed its initial public offering in 2013.
Is RDHL an ADR?
Yes — RDHL is an American Depositary Receipt; its underlying shares trade on a non-US exchange. RedHill Biopharma Ltd. reporting and dividends follow the underlying issuer.